EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The impact of external reference pricing on pharmaceutical costs and market dynamics

Dominic Voehler, Benjamin C Koethe, Patricia G Synnott, Daniel A Ollendorf

Health Policy OPEN · 2023-12 · 4 · 100093

DOI: 10.1016/j.hpopen.2023.100093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Policy OPEN, 2023-12. Verfasst von Dominic Voehler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washingto…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Commonwealth Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growth in the cost of prescription drugs in the US has generated significant interest in the use of external reference pricing (ERP) to tie prices paid for drugs to those in other countries. We used data from the Pricentric ONE™ database, an international drug pricing database, to examine product launch timing, launch price, and price changes from January 2010 - October 2021 in both ERP and non-ERP settings, with a focus on 100 high-priced drugs of interest to Medicare and Medicaid. We found that ERP policies were associated with a 73% reduction in the likelihood of drug launch within 9 months of regulatory approval relative to non-ERP settings. In addition, while ERP was associated with statistically significant reductions in annual drug price changes, such policies did not impact launch price. In addition, no single ERP feature (e.g., number of countries referenced, ERP calculation) was materially associated with the outcomes of interest. We conclude that ERP policies do not appear to impact drug launch price and may delay access to new therapies, raising questions about the utility of such policies in the US and potential consequences abroad.

Schlagwörter

Stichwörter der Autor:innen

Cost-effectivenessDrug pricingExternal reference pricingInternational reference pricingValue-based pricing

Autor:innen und Institutionen

  • Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St. #063, Boston, MA 02111, USA.
  • Biostatistics, Epidemiology, and Research Design Center, Tufts Clinical and Translational Science Institute (CTSI), Tufts Medical Center, 800 Washington St. #063, Boston, MA 02111, USA.

Förderung

  • Commonwealth Fund

Zitieren

APA

Voehler, D., Koethe, B. C., Synnott, P. G., & Ollendorf, D. A. (2023). The impact of external reference pricing on pharmaceutical costs and market dynamics. Health Policy OPEN, 4, 100093. https://doi.org/10.1016/j.hpopen.2023.100093

Vancouver

Voehler D, Koethe BC, Synnott PG, Ollendorf DA. The impact of external reference pricing on pharmaceutical costs and market dynamics. Health Policy OPEN. 2023;4:100093. doi:10.1016/j.hpopen.2023.100093

BibTeX
@article{Voehler2023,
  author = {Voehler, Dominic and Koethe, Benjamin C and Synnott, Patricia G and Ollendorf, Daniel A},
  title = {The impact of external reference pricing on pharmaceutical costs and market dynamics},
  journal = {Health Policy OPEN},
  year = {2023},
  volume = {4},
  pages = {100093},
  doi = {10.1016/j.hpopen.2023.100093}
}
Kostenlos starten →